Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness

Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness

Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness

Learn how to properly identify patients with HFrEF or worsening heart failure who may benefit from the recent emerging data on sGC stimulators.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Is it possible to reduce the nearly 60% one-month rehospitalization rates in patients with worsening heart failure? Dr. Paul Armstrong and Dr. Justin Ezekowitz discuss new therapeutic combinations including soluble guanylate cyclase (sGC) stimulators, as well as the practical applications of new evidence that was presented at the 2021 annual ACC meeting that may change how physicians approach treating their patients with worsening heart failure. Don’t miss out on new information about how sGC stimulators may benefit your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Paul W. Armstrong, MD
    Professor, Division of Cardiology
    University of Alberta
    Alberta, Canada 

    Contracted Research: Bayer, Merck

    Justin Ezekowitz, MD, MBBCh, MSc
    Professor of Medicine
    University of Alberta
    Alberta, Canada 

    Consulting Fees: Amgen, AstraZeneca, Bayer, Cytokinetics, Merck

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the most recent drug combinations for HF and guideline-based recommendations for their use
    • Understand mortality and morbidity data from recent clinical trials in patients with high-risk chronic HF
    • Discuss emerging data on new classes of agents and their role in the guideline-based treatment of chronic HF
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, primary care physicians, and all allied healthcare professionals involved in the care and diagnosis of heart failure.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free